We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Glucose Measurements Can Be Made From Tears

By LabMedica International staff writers
Posted on 23 Mar 2011
A new sensor would enable people to draw tear fluid from their eyes to get a glucose-level test sample. More...


Glucose in tear fluid may give an indication of glucose levels in the blood as accurately as a test using a blood sample.

The technology was designed by bioengineer Jeffrey T. LaBelle, a professor in the School of Biological and Health Systems Engineering, one of the Arizona State University (Tempe, AZ, USA) Ira A. Fulton Schools of Engineering.

Prof. LaBelle is leading the ASU-Mayo team along with Mayo Clinic (Scottsdale, AZ, USA) physicians Curtiss B. Cook, MD, an endocrinologist, and Dharmendra (Dave) Patel, MD, chair of Mayo's Department of Surgical Ophthalmology.

Many people with diabetes suffer due to the difficulty of managing their blood glucose levels. It is recommended that they monitor their own glucose levels, but current monitoring devices typically require patients to perform the painful task of pricking their finger to draw blood for a test sample —and many patients must do it several times each day.

"This new technology might encourage patients to check their blood sugars more often, which could lead to better control of their diabetes by a simple touch to the eye," said bioengineer Jeffrey T. LaBelle.

The major challenges are performing the test quickly, efficiently, with reproducible results, without letting the test sample evaporate and without stimulating a stress response that causes people to rub their eyes intensely, Prof. LaBelle said.

Because of its potential impact on health care, the technology has drawn interest from BioAccel (Phoenix, AZ, USA), an Arizona nonprofit that works to accelerate efforts to bring biomedical technologies to the marketplace.

"With funding provided by BioAccel, the scientific team will conduct critical experiments to determine how well the new device correlates with use of the current technology that uses blood sampling," said Ron King, BioAccel's chief scientific and business officer.

Related Links:

Arizona State University
Mayo Clinic
BioAccel



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Sepsis Test
SeptiCyte RAPID
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.